RT Book, Section
A1 Leavitt, Andrew D.
A1 Price, Erika Leemann
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184168651
T1 Acquired Disorders of Coagulation
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184168651
RD 2024/04/19
AB Patients  with  antiphospholipid  antibodies  occasionally  have  antibody  specificity  to  coagulation  factor  II  (prothrombin)  that  accelerates  factor  II  clearances  and  can  lead  to  severe  hypoprothrombinemia  and  bleeding.  Mixing  studies  may  or  may  not  reveal  presence  of  an  inhibitor,  as  the  antibody  typically  binds  a  non-enzymatically  active  portion  of  the  molecule  leading  to  accelerated  clearance,  but  characteristically  the  PT  is  prolonged  and  levels  of  factor  II  are  low.  FFP  should  be  administered  to  treat  bleeding.  Treatment  is  immunosuppressive.